ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BVS vs SGP // DIVIDEND YIELD & FCF PAYOUT SAFETY

Bioventus Inc. (Class A) (NASDAQ) VS. SpyGlass Pharma Inc. (NASDAQ) • 15-METRIC TALLY: BVS 4 — SGP 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BVS VS. SGP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BVS SGP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 68.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 10.40% -35.00% +45.40 BVS /roic <GO>
EV/EBITDA & P/E Valuation 26.3x — — TIE /valuation <GO>
Free Cash Flow Yield 5.77% -3.08% +8.85 BVS /fcf-yield <GO>
Operating Margin 9.50% — — TIE /operating-margins <GO>
Net Profit Margin 4.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -0.90% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.25 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 2/9 +5.00 BVS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.7 70.2 -24.50 SGP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 51.2x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.12B $1.08B $42.2M BVS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BVS REV SGP REV BVS GROSS % SGP GROSS % BVS FCF SGP FCF
FY 2025 $568.1M $116.1M 68.3% — $72.1M -$33.5M
FY 2024 $573.3M $75.8M 67.7% — $37.8M -$24.0M
FY 2023 $512.3M — — — $15.3M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BVS // BETA —
SGP // BETA —